Clinical Laserthermia Systems AB (OSTO:CLS B) EBIT: kr-39.77 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:CLS B Clinical Laserthermia Systems AB OSTO:CLS B
54 GF Score
Price kr1.93
GF Value kr2.67
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Clinical Laserthermia Systems AB EBIT?

Clinical Laserthermia Systems AB OSTO:CLS B -2.53% 54 EBIT is kr-39.77 Mil as of Jun. 2026. GuruFocus rates OSTO:CLS B with a GF Score™ of 54/100 and a GF Value™ of kr2.67 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Clinical Laserthermia Systems AB's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was kr-12.08 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-39.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Clinical Laserthermia Systems AB's annualized ROC % for the quarter that ended in Jun. 2026 was -106.99%. Clinical Laserthermia Systems AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -252.13%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Clinical Laserthermia Systems AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was -112.77%.


Clinical Laserthermia Systems AB  (OSTO:CLS B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Clinical Laserthermia Systems AB's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=-54.416 * ( 1 - 0% )/( (48.944 + 52.774)/ 2 )
=-54.416/50.859
=-106.99 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Clinical Laserthermia Systems AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-48.316/( ( (15.332 + max(3.302, 0)) + (19.692 + max(-8.008, 0)) )/ 2 )
=-48.316/( ( 18.634 + 19.692 )/ 2 )
=-48.316/19.163
=-252.13 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.059 + 9.926 + 2.24) - (5.466 + 0 + 4.457)
=3.302

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.336 + 8.868 + 2.24) - (15.381 + 0 + 10.071)
=-8.008

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Clinical Laserthermia Systems AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=-39.767/35.264
=-112.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Clinical Laserthermia Systems AB EBIT Related Terms


Clinical Laserthermia Systems AB EBIT Historical Data

* Premium members only.

The historical data trend for Clinical Laserthermia Systems AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clinical Laserthermia Systems AB EBIT Chart

Clinical Laserthermia Systems AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -57.74 -60.29 -71.12 -47.43 -41.95

Clinical Laserthermia Systems AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.32 -8.12 -12.20 -7.37 -12.08

OSTO:CLS B vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Clinical Laserthermia Systems AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clinical Laserthermia Systems AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Clinical Laserthermia Systems AB's EV-to-EBIT falls into.


OSTO:CLS B
54GF Score
Clinical Laserthermia Systems AB OSTO:CLS B
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clinical Laserthermia Systems AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-39.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-39.77 Mil mean?
Clinical Laserthermia Systems AB (OSTO:CLS B) has a EBIT of kr-39.77 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Clinical Laserthermia Systems AB.
Is Clinical Laserthermia Systems AB's EBIT too high?
Clinical Laserthermia Systems AB's current EBIT is kr-39.77 Mil. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's EBIT compare to ABT and SYK?
Clinical Laserthermia Systems AB's EBIT of kr-39.77 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Clinical Laserthermia Systems AB. Clinical Laserthermia Systems AB's current EBIT is kr-39.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (OSTO:CLS B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.67, compared to a current price of kr1.93 — trading 27.7% below its estimated fair value. The current EBIT is kr-39.77 Mil. Clinical Laserthermia Systems AB's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (OSTO:CLS B), the current EBIT is kr-39.77 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinical Laserthermia Systems AB (OSTO:CLS B) Overvalued in 2026?

Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued. The current stock price of kr1.93 is trading 27.7% below its estimated GF Value™ of kr2.67. GuruFocus considers Clinical Laserthermia Systems AB to be Modestly Undervalued.

Key valuation signals for OSTO:CLS B:

  • EBIT: kr-39.77 Mil
  • GF Value™: kr2.67 vs. price of kr1.93 (27.7% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the OSTO:CLS B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Clinical Laserthermia Systems AB Business Description

Other Exchanges LS60:Germany
Address Scheelevagen 2, Medicon village, Lund, SWE, 223 81
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
54GF Score

Get the complete analysis for OSTO:CLS B

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.93
Price
kr2.67
GF Value